JP2025508959A5 - - Google Patents

Info

Publication number
JP2025508959A5
JP2025508959A5 JP2024552157A JP2024552157A JP2025508959A5 JP 2025508959 A5 JP2025508959 A5 JP 2025508959A5 JP 2024552157 A JP2024552157 A JP 2024552157A JP 2024552157 A JP2024552157 A JP 2024552157A JP 2025508959 A5 JP2025508959 A5 JP 2025508959A5
Authority
JP
Japan
Prior art keywords
agent according
pharmaceutically acceptable
acceptable salt
stranded oligonucleotide
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552157A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508959A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/063531 external-priority patent/WO2023168304A2/en
Publication of JP2025508959A publication Critical patent/JP2025508959A/ja
Publication of JP2025508959A5 publication Critical patent/JP2025508959A5/ja
Pending legal-status Critical Current

Links

JP2024552157A 2022-03-02 2023-03-01 Ｍｓｈ３活性と関連するヌクレオチドリピート伸長障害の治療方法 Pending JP2025508959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263315707P 2022-03-02 2022-03-02
US63/315,707 2022-03-02
PCT/US2023/063531 WO2023168304A2 (en) 2022-03-02 2023-03-01 Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity

Publications (2)

Publication Number Publication Date
JP2025508959A JP2025508959A (ja) 2025-04-10
JP2025508959A5 true JP2025508959A5 (https=) 2026-03-10

Family

ID=87884356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552157A Pending JP2025508959A (ja) 2022-03-02 2023-03-01 Ｍｓｈ３活性と関連するヌクレオチドリピート伸長障害の治療方法

Country Status (4)

Country Link
US (1) US20250197856A1 (https=)
EP (1) EP4486893A2 (https=)
JP (1) JP2025508959A (https=)
WO (1) WO2023168304A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR122534A1 (es) 2020-06-03 2022-09-21 Triplet Therapeutics Inc Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1991677A2 (en) * 2006-01-26 2008-11-19 Isis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
JP7714162B6 (ja) * 2018-12-03 2025-09-08 タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド Ｍｓｈ３活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法
KR20210106437A (ko) * 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
AR122534A1 (es) * 2020-06-03 2022-09-21 Triplet Therapeutics Inc Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
EP4247392A4 (en) * 2020-06-03 2025-10-08 Takeda Pharmaceuticals Usa Inc METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY

Similar Documents

Publication Publication Date Title
JP7662069B2 (ja) 一本鎖オリゴヌクレオチド
JP2022518929A5 (https=)
JP7197463B2 (ja) Ｓｍｎ２の調節のための化合物及び方法
JP2020096629A5 (https=)
CN113286886B (zh) 用于减少朊病毒表达的化合物和方法
JP2019525918A5 (https=)
JP2023536472A5 (https=)
TW201923082A (zh) 用於降低snca表現之化合物及方法
JP2022533358A5 (https=)
JP2023536994A5 (https=)
JP2022527105A5 (https=)
JP2021511072A5 (https=)
JP2025508959A5 (https=)
CN116322707A (zh) 用于调节scn2a的化合物和方法
TW202140787A (zh) 用於調節ｓｍｎ２之化合物及方法
JP7211933B2 (ja) 転写プロセシングの調節のための化合物及び方法
WO2021153747A1 (ja) Ａｔｎ１のアンチセンスオリゴヌクレオチド
JP2022500079A (ja) Ｃｌｎ３の発現を調節するための化合物及び方法
JP2024522147A5 (https=)
JP2023542889A (ja) 複数の標的を介して疼痛を処置するための治療用組成物
JP2021510512A5 (https=)
JP2024536132A5 (https=)
JP2025511183A5 (https=)
JP2024543952A5 (https=)
WO2022211129A1 (ja) Ａｔｎ１のアンチセンスオリゴヌクレオチド誘導体